Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7762749 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL285806 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762757 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765483 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765477 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7767368 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7767298 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7765468 | 1.00 | EPHX1 (0.53) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762723 | 0.99 | EPHX1 (0.51) | EPHX1ATMRAB9AKMT2AUBE2M | |
| SCHEMBL7762720 | 0.99 | EPHX1 (0.51) | EPHX1ATMRAB9AKMT2AUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| EP-0718281-B1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS LTD (JP) | 2001-06-27 | — | — | EP | claimed |
| EP-0718281-A1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1996-06-26 | — | — | EP | claimed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-0718281-B1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS LTD (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-0718281-A1 | CYCLOHEXANEDIUREA DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | EPHX1 1363/4885ATM 488/4885RAB9A 2668/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | EPHX1 4255/4885ATM 587/4885RAB9A 1653/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | EPHX1 1053/4885ATM 2381/4885RAB9A 4035/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | EPHX1 466/4885ATM 4421/4885RAB9A 1869/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | EPHX1 900/4885ATM 3374/4885RAB9A 2942/4885 |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | ACAT2, ACAT1, LCAT | EPHX1 900/4885ATM 3374/4885RAB9A 2942/4885 |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | GLP1R, GPR119, FABP4 | EPHX1 1909/4885ATM 1989/4885RAB9A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.